Abstract
Difficulty in managing oral secretions is commonly experienced by patients with amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and associated bulbar weakness including dysphagia. There are no definitive evidence-based treatment guidelines to manage the distressing symptom of drooling. We reviewed the evidence for the effectiveness of botulinum toxin injections to reduce saliva in ALS/MND. The search strategy was conducted in four stages: (1) electronic search of relevant databases, (2) hand searches of all international ALS/MND symposium journals, (3) email request to MND care centres in the UK and Ireland, and (4) hand searching of reference lists. All studies were critically appraised and relevant data extracted. Botulinum toxin type A and type B were analysed separately. Due to heterogeneity, it was not possible to calculate a pooled estimate of effect. Twelve studies met the inclusion criteria (9 for type A and 3 for type B). Only two randomised controlled trials were identified. Study sample sizes were small with a mean of 12.5 subjects. The most frequently reported outcomes were weight of cotton rolls and number of tissues used. All studies claimed the intervention tested was effective, but only seven studies (4 for type A and 3 for type B) reported statistically significant differences. Although there is evidence to suggest that botulinum toxin B can reduce drooling, the evidence base is limited by a lack of randomized controlled trials. Evidence to support the use of botulinum toxin A is weaker. Larger trials will help remove the uncertainty practitioners face in treating this disabling symptom.
Similar content being viewed by others
References
Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:235–7.
Yorkston K, Miller R, Strand E. Management of speech and swallowing in degenerative diseases. Austin, TX: Pro-Ed; 1999.
Easterling C, Antinoja J, Cashin S, Barkhaus PE. Changes in tongue pressure, pulmonary function, and salivary flow in patients with amyotrophic lateral sclerosis. Dysphagia. 2013;28:217–25.
Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg BM, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Neurology. 1999;52:1311–23.
Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, Pradat PF, Silani V, Tomkin B. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12:921–38.
Elman L, Dubin R, Kelly M, McCluskey L. Management of oropharyngeal and tracheobronchial secretions in patients with neurologic disease. J Palliat Med. 2005;8:1150–9.
Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment - botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997;48:337–9.
Thomas H. Quality assessment tool for quantitative studies. Toronto, ON: Effective Public Health Practice Project; 2003.
Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(iii–x):1–173.
Contarino M, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A, Rapaccini G, Gasbarrini G, Tonali P, Bentivoglio A. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:299–303.
Costa J, Rocha M, Ferreira J, Evangelista T, Coelho M, de Carvalho M. Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis. J Neurol. 2008;255:545–50.
Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka K. Injections of botulinum toxin A into the salivary glands to improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:121–3.
Rowe D, Erjavec S. An open-label pilot study of intra-parotid botulinum toxin A injections in the treatment of sialorrhoea in motor neurone disease. Milan: The fourteenth International Symposium on ALS/MND; 2003.
Scott K, Kothari M, Venkatesh Y, Murphy T, Simmons Z. Parotid gland injections of botulinum toxin A are effective in treating sialorrhea in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis. 2005;7:62–5.
Gilio F, Iacovelli E, Frasca V, Gabriele M, Giacomelli E, Picchiori F, Soldo P, Cipriani AM, Ruoppolo G, Inghilleri M. Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. Amyotroph Lateral Scler. 2010;11:359–63.
Rodriguez-Murphy E, Marti-Bonmati E, Camps-Segui E, Bagan JV. Manually guided botulinum toxin type A submandibular injections for the treatment of sialorrhea in tube-fed patients with advanced amyotrophic lateral sclerosis. Am J Health Syst Pharm. 2011;68:1680–1.
Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. Eur J Neurol. 2007;14:1373–7.
Weikamp J, Schinagl D, de Swart B, Schelhaas H, Zwarts M. A prospective, randomised controlled study comparing radiotherapy with botulinum toxin A as a treatment for drooling in ALS. Amyotroph Lateral Scler. 2008;9:152.
Levitsky G, Alekhin A, Serdyuk A, Skvortsova V. Open-label comparative study of Amitriptyline and Dysport efficacy in control of sialorrhea in ALS. Amyotroph Lateral Scler. 2005;6(Suppl 1):154.
Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, McVey A, Kittrell PP, King R, Herbelin L. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39:137–43.
Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190:95–7.
Meijer J, Van Kuijk A, Geurts A, Schelhaas H, Zwarts M. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008;87:321–4.
Winterholler M, Erbguth FJ, Wolf S, Kat S, Naumann M, Geiss R, Schwager K, Toyka Kv. Botulinum toxin for the treatment of sialorrhea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry. 2001;70:417–8.
Guidubaldi A, Fasano A, Lalongo T, Piano C, Pompili M, Masciana R, Siciliani L. Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Mov Disord. 2011;26:313–9.
Sterne J, Egger M, Davey Smith G. Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101–5.
Stone C, O’Leary N. Systematic review of the effectiveness of botulinum toxin and radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manag. 2009;37:246–58.
Young C, Ellis C, Johnson J, Sathasivam S, Pih N. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev. 2011;5:CD006981.
Norris SL, Atkins D. Challenges in using nonrandomized studies in systematic reviews of treatment interventions. Ann Intern Med. 2005;142:1112–9.
Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions, ver. 5.0.2. Oxford: The Cochrane Collaboration; 2009.
Swash M. We have a problem: Why have ALS trials been negative? Amyotroph Lateral Scler. 2007;8:259.
Acknowledgments
We thank Sheila Lloyd, Librarian at the Motor Neurone Disease Association, and Julia Johnson, Specialist Speech and Language Therapist at Kings College Hospital, London, for assisting in identifying relevant papers, and Nicola Darlington, Librarian at the University of Nottingham, for refining the search strategy.
Conflict of interest
The authors have no conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Squires, N., Humberstone, M., Wills, A. et al. The Use of Botulinum Toxin Injections to Manage Drooling in Amyotrophic Lateral Sclerosis/Motor Neurone Disease: A Systematic Review. Dysphagia 29, 500–508 (2014). https://doi.org/10.1007/s00455-014-9535-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00455-014-9535-8